EntreMed announced issurance of U.S. patent for 2ME2

theflyonthewall.com

EntreMed announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol. Patent No. 8,399,440, entitled "Disease Modifying Anti-Arthritic Activity of 2-Methoxyestradiol," was granted on March 19, 2013, by the U.S. Patent & Trademark Office and contains composition and method claims covering the combination of 2ME2 and methotrexate for the treatment of rheumatic diseases, including rheumatoid arthritis.

Rates

View Comments (0)